p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors

International Journal of Cancer

Volumn 124, Issue 4, 2009, Pages 991-997

  Varna, Mariana ^a   Lehmann Che, Jacqueline ^b,c   Turpin, Elisabeth ^b,c   Marangonl, Elizabetha ^d   El Bouchtaoui, Morad ^a   Jeanne, Marion ^b   Grigoriu, Carmen ^a,c   Ratajczak, Philippe ^a   Leboeuf, Christophe ^a   Plassa, Louis Francois ^c   Ferreira, Irmine ^a   Poupon, Marie France ^d   Janin, Anne ^a,c   De The, Hugues ^b,c   Bertheau, Philippe ^a,c  

^a INSERM   (France)

^b CNRS   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSTITUT CURIE   (France)

Author keywords

Breast; Cyclophosphamide; Epirubicin; p53; Senescence; Xenograft

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOPHOSPHAMIDE; EPIRUBICIN; PROTEIN P53; ANTINEOPLASTIC AGENT; DNA; TP53 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL AGING; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MEGADOSE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TISSUE SECTION; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; EXPERIMENTAL NEOPLASM; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL AGING; CELL CYCLE; CYCLOPHOSPHAMIDE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EPIRUBICIN; GENES, P53; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MUTATION; NEOPLASM TRANSPLANTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149477219     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24049     Document Type: Article

References (30)

1. Kaufmann M, von Minckwitz G, Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 2005; 14:576-81.
2. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006;6:409-14.
3. Bertheau P, Lerebours F, Mounier N, de Roquancourt A, Espie M, Clot P, Servant JM, Misset JL, Marly M, Janin A. Prognostic significance of a combined clinieopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep 2005:14:513-20.
4. Brown JM, Attardi LD, The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7.
5. Collado M. Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130:223-33.
6. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008;8:450-8.
7. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 2008;8:512-22.
8. Cichowski K, Hahn WC. Unexpected pieces to the senescence puzzle. Cell 2008;133:958-61.
9. Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ 2006;13:1017-26.
10. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medium EE, Linskens M, Rubelj I, Pereira-Smith O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363-7.
11. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003;63:2705-15.
12. Chen QM, Liu J, Merrett JB. Apoptosis or senescence-like growth arrest: influence of cell-cycle position, p53, p21 and bax in H202 response of normal human fibroblasts. Biochem J 2000;347:543-51.
13. Hattangadi DK, DeMasters GA, Walker TD, Jones KR, Di X, Newsham IF, Gewirtz DA. Influence of p53 and caspase 3 activity on cell death and senescence in response to methotrexate in the breast tumor cell. Biochem Pharmacol 2004;68:1699-708.
14. Leal JF, Fominaya J, Gascon A, Guijarro MV, Blanco-Aparicio C, Lleonart M, Castro ME, Ramon YCS, Robledo M, Beach DH, Carnero A. Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene 2008:27:1961-70.
15. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 2008;27:2801-9.
16. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M. Tumour biology: senescence in premalignant tumours. Nature 2005:436:642.
17. Zhang H. Molecular signaling and genetic pathways of senescence: Its role in tumorigenesis and aging. J Cell Physiol 2007;210:567-574.
18. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62:1876-83.
19. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, Holt SE. Adriamycin-mduced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002;277:35509-15.
20. Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de The H. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002;360:852-4.
21. Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLo S Med 2007;4:e90.
22. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, et al. A new model of patient tumorderived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007;13:3989-98.
23. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995;92:3963-7.
24. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressier L, Akslen LA, Ragaz. J, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
25. Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T, Ushio Y, Saya H. Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene 2004;23: 6548-58.
26. Castedo M, Perfettini JL, Roumier T, Yakushijin K, Home D, Medema R, Kroeraer G. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 2004;23:4353- 61.
27. Moreno CS, Matyunina L, Dickerson EB, Schubert N, Bowen NJ, Logani S, Benigno BB, McDonald JF. Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLo S ONE 2007;2:e441.
28. Middelburg R, de Haas RR, Dekker H, Kerkhoven RM, Pohlmann PR, Fuentes-Alburo A, Mohar A, Pinedo HM, Lankelma J. Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 2005;11:1863-1869.
29. Varna M, Soliman H, Feugeas JP, Turpin E, Chapelin D, Legres L, Plassa LF, de Roquancourt A, Espie M, Misset JL, Janin A, de The H, et al. Changes in allelic imbalances in locally advanced breast cancers after chemotherapy. Br. J Cancer 2007;97:1157-1164.
30. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-269.